← Back to Search

Arsenic Trioxide

Arsenic Trioxide for Blood Cancer

Phase 2
Waitlist Available
Research Sponsored by Our Lady of Mercy Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Hepatic criteria: Bilirubin no greater than 2.0 mg/dL (except for leukemic infiltration dysfunction), Alkaline phosphatase less than 2 times upper limit of normal (except for leukemic infiltration dysfunction)
Age 18 and over
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying how well arsenic trioxide works in treating patients with cancer.

Who is the study for?
This trial is for adults over 18 with certain blood cancers like acute leukemia, chronic myeloid leukemia, lymphoma, or myeloma that have come back or didn't respond to treatment. They should not be pregnant, must use birth control if fertile, and can't have active infections or a history of seizures. Their kidney and liver functions need to meet specific criteria.Check my eligibility
What is being tested?
The trial is testing the effectiveness of arsenic trioxide in patients whose blood cancers have returned after treatment or did not respond at all. It's a Phase II study which means they're looking at how well it works and what dose is best.See study design
What are the potential side effects?
Arsenic trioxide may cause side effects such as fatigue, nausea, vomiting, diarrhea, heart issues (like abnormal rhythms), headaches, dizziness and numbness in hands/feet. Some people might experience changes in their blood counts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My liver functions, including bilirubin and alkaline phosphatase levels, are within the required range.
Select...
I am 18 years old or older.
Select...
My creatinine level is 2.0 mg/dL or lower.
Select...
My condition is a type of blood cancer that has come back or didn't respond to treatment.
Select...
I am able to get out of my bed or chair and move around.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Our Lady of Mercy Medical CenterLead Sponsor
1 Previous Clinical Trials
123 Total Patients Enrolled
Janice P. Dutcher, MDStudy ChairOur Lady of Mercy Medical Center

Media Library

Arsenic Trioxide (Arsenic Trioxide) Clinical Trial Eligibility Overview. Trial Name: NCT00003885 — Phase 2
Myelodysplastic Syndrome Research Study Groups:
Myelodysplastic Syndrome Clinical Trial 2023: Arsenic Trioxide Highlights & Side Effects. Trial Name: NCT00003885 — Phase 2
Arsenic Trioxide (Arsenic Trioxide) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00003885 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any enrollment opportunities available for this clinical experiment?

"Clinicaltrials.gov displays that this medical study is no longer recruiting participants, having first been listed on November 1st 1997 and last updated in 2013. However, there are 3,636 other trials accepting volunteers at the present moment."

Answered by AI

Has this medicinal protocol been sanctioned by the FDA?

"Our evaluation has determined that the safety of this treatment is moderate, receiving a score of 2. This finding is supported by Phase 2 trial results indicating data backing safety but not efficacy."

Answered by AI
~2 spots leftby Mar 2025